Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pieris’ Asthma Product Withheld from Trials by AstraZeneca

Pieris’ Asthma Product Withheld from Trials by AstraZeneca

28th June 2023

To obtain the rights to elarekibep, AstraZeneca partnered with Pieris back in 2017 and paid them $45 million. Pieris believed they had created a medication to treat IL-4Ra, which is linked to type 2 endotype asthma and can be found in high quantities in the airways.

However, after acquiring results from toxicity research, AstraZeneca has stopped the clinical trials of its prospective asthma treatment, elarekibep.

Although there were no clinical findings in the nonhuman primate investigation, “respiratory tract pathology findings” were discovered, lung tissue inflammation.

However, the harm caused to primates that were given elarekibep through the use of a dry powder inhaler did not seem to change based on dose size.

Pieris said the findings “are not a concern for the active clinical studies but do not support long-term use and progression to later-stage development,” although they have since discontinued and stopped dosing in ongoing clinical studies of elarekibep.

Shares recently dropped from 89 to 37 cents, a total of 58% to 37 cents as a result of this.

They reported: “Pieris will expedite a review of the implications of the data and AstraZeneca’s decision on the program and will review its overall corporate priorities prior to sharing a further update.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.